GLPG Stock Overview
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Galapagos NV Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €28.77 |
| 52 Week High | €45.21 |
| 52 Week Low | €28.30 |
| Beta | 0.021 |
| 1 Month Change | -7.55% |
| 3 Month Change | -27.55% |
| 1 Year Change | -28.98% |
| 3 Year Change | -62.23% |
| 5 Year Change | -74.51% |
| Change since IPO | 266.50% |
Recent News & Updates
Recent updates
Galapagos: Pipeline Still Progressing Despite Financial Volatility
Mar 07Galapagos: Trading At Discount To Cash With A Fast-Growing Marketed Product
Oct 10EMA panel approves amending label for Galapagos' Jyseleca on testicular function effects
Oct 03Galapagos stock dips after Jefferies slashes rating citing challenges ahead
Jul 25Galapagos: Can The Company Turn Around?
May 19Galapagos: A History Of Disruptive Failures
Feb 22Galapagos: The Investment Thesis Is More Appealing Than Ever
Dec 02Galapagos, Gilead's Selection study on filgotinib in ulcerative colitis published in the Lancet
Jun 04Galapagos reports Q1 results
May 06Galapagos: Market Values Pipeline Below $0
Dec 30Galapagos candidate shows positive action in IPF proof-of-concept study
Nov 30Galapagos NV 2020 Q3 - Results - Earnings Call Presentation
Nov 06Galapagos Is A Buy Despite Setback In The U.S.
Oct 23Shareholder Returns
| GLPG | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -1.1% | 0.5% | 2.7% |
| 1Y | -29.0% | 3.4% | 26.0% |
Return vs Industry: GLPG underperformed the US Biotechs industry which returned 3% over the past year.
Return vs Market: GLPG underperformed the US Market which returned 25% over the past year.
Price Volatility
| GLPG volatility | |
|---|---|
| GLPG Average Weekly Movement | 3.4% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: GLPG's share price has been volatile over the past 3 months.
Volatility Over Time: GLPG's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 1,123 | Paul Stoffels | www.glpg.com |
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company’s pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l.
Galapagos NV Fundamentals Summary
| GLPG fundamental statistics | |
|---|---|
| Market cap | US$1.91b |
| Earnings (TTM) | US$33.11m |
| Revenue (TTM) | US$262.65m |
57.5x
P/E Ratio7.3x
P/S RatioIs GLPG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GLPG income statement (TTM) | |
|---|---|
| Revenue | €243.58m |
| Cost of Revenue | €243.84m |
| Gross Profit | -€260.00k |
| Other Expenses | -€30.97m |
| Earnings | €30.71m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 01, 2024
| Earnings per share (EPS) | 0.47 |
| Gross Margin | -0.11% |
| Net Profit Margin | 12.61% |
| Debt/Equity Ratio | 0% |
How did GLPG perform over the long term?
See historical performance and comparison